- Home
- RLGT vs DMAC Comparison
RLGT vs DMAC Comparison
Compare RLGT & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLGT | DMAC |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.9M | 352.1M |
| IPO Year | 2006 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RLGT | DMAC |
|---|---|---|
| Price | $9.24 | $8.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $11.00 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 333.7K | 201.4K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.43 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $934,356,000.00 | $500,000.00 |
| Revenue This Year | $4.96 | N/A |
| Revenue Next Year | $4.98 | N/A |
| P/E Ratio | $24.18 | ★ N/A |
| Revenue Growth | ★ 3.51 | N/A |
| 52 Week Low | $5.86 | $5.25 |
| 52 Week High | $10.20 | $10.42 |
Technical Indicators
Market Signals| Indicator | RLGT | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 58.47 | 64.96 |
| Support Level | $8.09 | $7.42 |
| Resistance Level | $9.56 | $8.47 |
| Average True Range (ATR) | 0.23 | 0.49 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 73.71 | 72.93 |
Price Performance
Historical ComparisonAbout RLGT Radiant Logistics Inc.
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services, including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.